{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:40:31Z","timestamp":1735674031723,"version":"3.32.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.gtc.2004.05.002","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:30Z","timestamp":1113836010000},"page":"629-654","source":"Crossref","is-referenced-by-count":8,"title":["Antiviral therapy in patients with chronic hepatitis B and cirrhosis"],"prefix":"10.1016","volume":"33","author":[{"given":"Cindy J.","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.gtc.2004.05.002_BIB1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(95)90401-8","article-title":"Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus","volume":"109","author":"Perrillo","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB3","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1046\/j.1440-1746.2000.02104.x","article-title":"Treatment of chronic hepatitis B virus infection in special groups of patients: decompensated cirrhosis, immunosuppressed and paediatric patients","volume":"15","author":"Merican","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0270-9139(95)90411-5","article-title":"Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB6","first-page":"560","article-title":"Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients","volume":"86","author":"Moreno-Otero","year":"1991","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","article-title":"Outcome of anti-HBe-positive chronic hepatitis B in alfa-interferon treated and untreated patients: a long-term cohort study","volume":"36","author":"Brunetto","year":"2002","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"de Jongh","year":"1992","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"issue":"26","key":"10.1016\/j.gtc.2004.05.002_BIB10","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.05.002_BIB11","first-page":"1316","article-title":"Hepatitis B virus transgenic mice: insights into the virus and the disease","volume":"22","author":"Chisari","year":"1995","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/0016-5085(87)90250-2","article-title":"Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy","volume":"93","author":"Di Bisceglie","year":"1987","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0016-5085(91)80022-2","article-title":"Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.gtc.2004.05.002_BIB14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB15","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/0016-5085(92)90337-X","article-title":"A controlled trial of interferon with or without prednisone priming for chronic hepatitis B","volume":"102","author":"Lok","year":"1992","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group","volume":"323","author":"Perrillo","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF01316785","article-title":"Interferon in the management of chronic hepatitis B","volume":"38","author":"Perrillo","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0168-8278(94)80114-2","article-title":"The treatment effect of alfa interferon in chronic hepatitis B is independent of pretreatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep)","volume":"21","author":"Krogsgaard","year":"1994","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/0016-5085(93)90281-G","article-title":"Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B","volume":"104","author":"Hoofnagle","year":"1993","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","article-title":"Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?","volume":"34","author":"Nair","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1086\/315742","article-title":"In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease","volume":"182","author":"Fiuza","year":"2000","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/gut.50.5.707","article-title":"Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome","volume":"50","author":"Trevisani","year":"2002","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","article-title":"Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B.A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7326\/0003-4819-115-2-113","article-title":"Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen","volume":"115","author":"Perrillo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB28","first-page":"324","article-title":"Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alfa interferon with or without corticosteroids: short- and long-term follow-up","volume":"28","author":"Zavaglia","year":"1996","journal-title":"Ital J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2003-37584","article-title":"Treatment of HBeAg-negative chronic hepatitis B","volume":"23","author":"Hadziyannis","year":"2003","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2893.2001.00299.x","article-title":"Therapeutic management of hepatitis B-related cirrhosis","volume":"8","author":"Merle","year":"2001","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2004.05.002_BIB31","first-page":"42","article-title":"Treatment of chronic anti-HBe-positive hepatitis B with interferon-alfa","volume":"22","author":"Brunetto","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2004.05.002_BIB32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0168-8278(92)90161-H","article-title":"Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon","volume":"14","author":"Pastore","year":"1992","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2004.05.002_BIB33","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/0168-8278(90)90180-Y","article-title":"Interferon alfa-2b treatment of HBeAg negative\/serum HBV DNA positive chronic active hepatitis type B","volume":"11","author":"Hadziyannis","year":"1990","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB35","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.510260634","article-title":"A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum","volume":"26","author":"Lampertico","year":"1997","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","article-title":"Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy","volume":"37","author":"Lampertico","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon alfa-treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0016-5085(93)90903-P","article-title":"Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B","volume":"105","author":"Brunetto","year":"1993","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB40","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.1840160605","article-title":"Clearance of HBsAg in seven patients with chronic hepatitis B","volume":"16","author":"Adachi","year":"1992","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0168-8278(86)80053-8","article-title":"Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma","volume":"2","author":"Dunk","year":"1986","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.1840170307","article-title":"Recombinant interferon alfa in inoperable hepatocellular carcinoma: a randomized controlled trial","volume":"17","author":"Lai","year":"1993","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach","volume":"34","author":"Camma","year":"2001","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G","article-title":"Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study","volume":"82","author":"Ikeda","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.gtc.2004.05.002_BIB45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-134-10-200105150-00010","article-title":"Effects of long-term postoperative interferon alfa therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial","volume":"134","author":"Kubo","year":"2001","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3748\/wjg.v9.i4.635","article-title":"Preventive treatments for recurrence after curative resection of hepatocellular carcinoma\u2014a literature review of randomized control trials","volume":"9","author":"Sun","year":"2003","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/jhep.2000.9409","article-title":"Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor\u2014a prospective randomized study of hepatitis C virus-related liver cancer","volume":"32","author":"Ikeda","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0676.1993.tb00599.x","article-title":"Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alfa","volume":"13","author":"Nevens","year":"1993","journal-title":"Liver"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2004.05.002_BIB49","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1136\/gut.34.2_Suppl.S104","article-title":"Interferon alfa-2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of a pilot study","volume":"34","author":"Dimopoulou","year":"1993","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB50","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0168-8278(97)80476-X","article-title":"Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns","volume":"26","author":"Honkoop","year":"1997","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00004836-200004000-00006","article-title":"Antiviral therapy of HBV- and HCV-induced liver cirrhosis","volume":"30","author":"Zavaglia","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB52","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1053\/gast.1997.v113.pm9322520","article-title":"Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study","volume":"113","author":"Nevens","year":"1997","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2004.05.002_BIB53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2893.1997.tb00156.x","article-title":"Prolonged interferon alfa therapy of hepatitis B virus-related decompensated cirrhosis","volume":"4","author":"Marcellin","year":"1997","journal-title":"J Viral Hepat"},{"issue":"1 Pt 3","key":"10.1016\/j.gtc.2004.05.002_BIB54","first-page":"2387","article-title":"Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts","volume":"19","author":"Lauchart","year":"1987","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(92)90138-F","article-title":"Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications","volume":"14","author":"O'Grady","year":"1992","journal-title":"J Hepatol"},{"issue":"8745","key":"10.1016\/j.gtc.2004.05.002_BIB56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","article-title":"Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients","volume":"337","author":"Samuel","year":"1991","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB57","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0016-5085(91)90611-N","article-title":"Persistent hepatitis B virus following interferon alfa therapy and liver transplantation","volume":"100","author":"Lavine","year":"1991","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.1840190103","article-title":"Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease","volume":"19","author":"Marcellin","year":"1994","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.gtc.2004.05.002_BIB60","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00000658-200205000-00002","article-title":"New era of liver transplantation for hepatitis B: a 17-year single-center experience","volume":"235","author":"Anselmo","year":"2002","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.gtc.2004.05.002_BIB63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/00007890-199611270-00013","article-title":"Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation","volume":"62","author":"Bain","year":"1996","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jlts.2002.32983","article-title":"Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B","volume":"8","author":"Fontana","year":"2002","journal-title":"Liver Transpl"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2004.05.002_BIB65","first-page":"67","article-title":"Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B","volume":"12","author":"Liaw","year":"2001","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.gtc.2004.05.002_BIB66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1053\/jhep.2000.17912","article-title":"Long-term therapy of chronic hepatitis B with lamivudine","volume":"32","author":"Lau","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB67","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jhep.2000.17915","article-title":"Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"32","author":"Hadziyannis","year":"2000","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB69","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.510300427","article-title":"Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy","volume":"30","author":"Dienstag","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB70","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multi-center United States\u2013Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B","volume":"33","author":"Perrillo","year":"2001","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB71","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group","volume":"29","author":"Tassopoulos","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB72","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510300221","article-title":"Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy","volume":"30","author":"Liaw","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB73","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1572-0241.2001.03806.x","article-title":"Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity","volume":"96","author":"Ormseth","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB74","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","article-title":"Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial","volume":"46","author":"Schalm","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.05.002_BIB75","first-page":"317A","article-title":"Predictors of HBsAg seroconversion in chronic hepatitis B patients treated with lamivudine","volume":"30","author":"Perrillo","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB76","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jmv.2164","article-title":"Efficacy of lamivudine in HBeAg-negative chronic hepatitis B","volume":"66","author":"Rizzetto","year":"2002","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0168-8278(00)80076-8","article-title":"Long-term follow-up of patients with anti-HBe\/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine","volume":"32","author":"Santantonio","year":"2000","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0168-8278(99)80123-8","article-title":"Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection","volume":"30","author":"Suzuki","year":"1999","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8278(00)80371-2","article-title":"Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection","volume":"33","author":"Yao","year":"2000","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.510310130","article-title":"Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B","volume":"31","author":"Villeneuve","year":"2000","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB82","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0168-8278(00)80372-4","article-title":"Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis","volume":"33","author":"Kapoor","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2004.05.002_BIB83","first-page":"301A","article-title":"Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B","volume":"30","author":"Perrillo","year":"1999","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.gtc.2004.05.002_BIB84","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1097\/00007890-200006150-00028","article-title":"Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis","volume":"69","author":"Kitay-Cohen","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB85","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort","volume":"34","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"9036","key":"10.1016\/j.gtc.2004.05.002_BIB86","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)04444-3","article-title":"Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis","volume":"348","author":"Grellier","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gtc.2004.05.002_BIB87","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0168-8278(99)80204-9","article-title":"High pretreatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation","volume":"30","author":"Mutimer","year":"1999","journal-title":"J Hepatol"},{"issue":"25","key":"10.1016\/j.gtc.2004.05.002_BIB88","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2003.50035","article-title":"Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B","volume":"37","author":"Lo","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2004.05.002_BIB90","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.510240339","article-title":"Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine","volume":"24","author":"Ling","year":"1996","journal-title":"Hepatology"},{"issue":"9044","key":"10.1016\/j.gtc.2004.05.002_BIB91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(96)02266-0","article-title":"Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation","volume":"349","author":"Bartholomew","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB92","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00007890-200009150-00018","article-title":"Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up","volume":"70","author":"Mutimer","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB93","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.510280241","article-title":"Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin","volume":"28","author":"Markowitz","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB94","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/lt.500050605","article-title":"Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation","volume":"5","author":"Yao","year":"1999","journal-title":"Liver Transpl Surg"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB95","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/jlts.2000.18702","article-title":"An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy","volume":"6","author":"Han","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gtc.2004.05.002_BIB96","first-page":"317A","article-title":"Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies","volume":"28","author":"Heathcote","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB97","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.510280629","article-title":"Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro","volume":"28","author":"Xiong","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2893.1999.00182.x","article-title":"A placebo-controlled phase I\/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection","volume":"6","author":"Gilson","year":"1999","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.1016\/j.gtc.2004.05.002_BIB99","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.gtc.2004.05.002_BIB100","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.05.002_BIB101","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/jhep.2003.09040","article-title":"Adefovir dipivoxil for the treatment of lamivudine-resistant HBV in chronic hepatitis B patients pre- and postliver transplantation","volume":"38","author":"Schiff","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/jhep.2000.8626","article-title":"Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants","volume":"32","author":"Perrillo","year":"2000","journal-title":"Hepatology"},{"issue":"1145","key":"10.1016\/j.gtc.2004.05.002_BIB103","first-page":"105","article-title":"(Hepsera) for chronic hepatitis B infection","volume":"44","author":"Adefovir","year":"2002","journal-title":"The Medical Letter"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB104","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB105","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/gast.2002.37058","article-title":"Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection","volume":"123","author":"Lai","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB106","first-page":"300A","article-title":"Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine","volume":"36","author":"Chang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB107","first-page":"349A","article-title":"A randomized, double-blind, comparison of 3 doses of emtricitabine (FTC) in patients with chronic hepatitis B given 48 weeks of treatment (FTCB-102)","volume":"34","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB108","first-page":"372A","article-title":"Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients given once daily emtricitabine for 2 years","volume":"36","author":"Gish","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","article-title":"Lamivudine, adefovir and tenofovir exhibit long-lasting antihepatitis B virus activity in cell culture","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB110","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB111","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/gast.2003.1240586b","article-title":"Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation","volume":"124","author":"Van Bommel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.05.002_BIB112","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1007\/BF00687123","article-title":"Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of wellferon in the prophylaxis of high-risk precancerous conditions","volume":"31","author":"Oon","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.gtc.2004.05.002_BIB113","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(96)80022-5","article-title":"Alfa interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis","volume":"24","author":"Mazzella","year":"1996","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB114","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/hep.510260536","article-title":"Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)","volume":"26","author":"Fattovich","year":"1997","journal-title":"Hepatology"},{"issue":"9115","key":"10.1016\/j.gtc.2004.05.002_BIB115","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(98)07236-5","article-title":"Effect of interferon-alfa on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alfa Hepatocellular Carcinoma Study Group","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gtc.2004.05.002_BIB116","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<901::AID-CNCR15>3.0.CO;2-Z","article-title":"Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis","volume":"83","author":"Benvegnu","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gtc.2004.05.002_BIB117","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510300109","article-title":"The long-term course of chronic hepatitis B","volume":"30","author":"Di Marco","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2004.05.002_BIB118","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/jlts.2000.18501","article-title":"Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine","volume":"6","author":"Sponseller","year":"2000","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.gtc.2004.05.002_BIB119","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/00007890-200210270-00011","article-title":"Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation","volume":"74","author":"Andreone","year":"2002","journal-title":"Transplantation"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:58:07Z","timestamp":1735671487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855304000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0889855304000652"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2004.05.002","relation":{},"ISSN":["0889-8553"],"issn-type":[{"type":"print","value":"0889-8553"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}